Ro 0437626

MedChemExpress

Cat. No.:	HY-108673	$\langle \rangle$
CAS No.:	134362-79-1	
Molecular Formula:	C ₂₇ H ₃₅ N ₅ O ₄ S	HN
Molecular Weight:	525.66	
Target:	P2X Receptor	
Pathway:	Membrane Transporter/Ion Channel	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	N S

BIOLOGICAL ACTIVITY				
Description	Ro 0437626 is a selective purinergic (P2X ₁) receptor antagonist (IC ₅₀ = 3 μ M), but shows low affinity for P2X2, P2X3 and P2X2/3 receptors (IC ₅₀ > 100 μ M) ^[1] .			
IC ₅₀ & Target	IC50: 3 µM (P2X1 receptor)			
In Vitro	Ro 0437626 reduces PMA-evoked Ca ²⁺ entry with 6.8 ± 4.7% of control ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
In Vivo	Ro 0437626 (1 and 10 μmol/kg; i.v.) causes a reduction in postinfusion isovolumetric contractions ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
	Animal Model:	Female rat (urethane-anaesthetized) ^[3]		
	Dosage:	1 and 10 μmol/kg		
	Administration:	l.v.		
	Result:	Caused a reduction in postinfusion isovolumetric contractions.		

REFERENCES

[1]. Jaime-Figueroa S, et al. Discovery and synthesis of a novel and selective drug-like P2X(1) antagonist. Bioorg Med Chem Lett. 2005;15(13):3292-3295.

[2]. Harper MT, et al. Phorbol ester-evoked Ca2+ signaling in human platelets is via autocrine activation of P(2X1) receptors, not a novel non-capacitative Ca2+ entry. J Thromb Haemost. 2010;8(7):1604-1613.

[3]. King BF, et al. Investigation of the effects of P2 purinoceptor ligands on the micturition reflex in female urethane-anaesthetized rats. Br J Pharmacol. 2004;142(3):519-530.

HO

ΟH

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA